© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
January 15, 2021
Community support is the most important factor in ascertaining effective treatments for paediatric eye diseases.
January 13, 2021
Diabetes mellitus, which is a common chronic disease in children, can lead to significant eye morbidities with long-lasting effects, including diabetic retinopathy. Treatment should be tailored to the individual patient.
January 06, 2021
Faricimab is the focus of the YOSEMITE and RHINE studies, which investigators say show that the investigational bispecific antibody has the potential to offer lasting vision improvements for patients with diabetic macular oedema.
January 04, 2021
Prospective randomised trial demonstrates clinical equivalence of biosimilar and reference ranibizumab
December 09, 2020
Good early adherence to label regimens can make a difference, yielding vision outcomes approaching those in clinical trials, emerging real-world studies of anti-VEGF for DMO suggest.
December 03, 2020
As OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.
November 25, 2020
In this roundtable, members of the Ophthalmology Times Europe® Editorial Advisory Board consider the top challenges and opportunities that they anticipate will affect ophthalmology in Europe in 2021.
November 15, 2020
Bradley Smith, MD, presents at AAO 2020 on how fingolimod 0.5 mg, a first-line treatment for multiple sclerosis, may reduce both the number of relapses and disease progression in patients with relapsing-remitting MS as well as the incidence of uveitis.
November 15, 2020
A case series of 13 young patients with Charles Bonnet syndrome, which is characterised by visual hallucinations in individuals who are experiencing sight loss, showed that the patients all had inherited retinal diseases or congenital eye disorders but there was no link with visual dysfunction.
November 15, 2020
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.